These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 20005725)

  • 21. Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors.
    Gustin DJ; Ma Z; Min X; Li Y; Hedberg C; Guimaraes C; Porter AC; Lindstrom M; Lester-Zeiner D; Xu G; Carlson TJ; Xiao S; Meleza C; Connors R; Wang Z; Kayser F
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2492-6. PubMed ID: 21392988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigations on the metabolic stability of cytosolic phospholipase A2α inhibitors with 1-indolylpropan-2-one structure.
    Fabian J; Hanekamp W; Thomas MH; Olivier JL; Lehr M
    Chem Biol Interact; 2013 Nov; 206(2):356-63. PubMed ID: 24120545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chiral 3-(4,5-dihydrooxazol-2-yl)phenyl alkylcarbamates as novel FAAH inhibitors: Insight into FAAH enantioselectivity by molecular docking and interaction fields.
    Myllymäki MJ; Käsnänen H; Kataja AO; Lahtela-Kakkonen M; Saario SM; Poso A; Koskinen AM
    Eur J Med Chem; 2009 Oct; 44(10):4179-91. PubMed ID: 19539407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies.
    Mor M; Rivara S; Lodola A; Plazzi PV; Tarzia G; Duranti A; Tontini A; Piersanti G; Kathuria S; Piomelli D
    J Med Chem; 2004 Oct; 47(21):4998-5008. PubMed ID: 15456244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality.
    Maryanoff BE; Costanzo MJ
    Bioorg Med Chem; 2008 Feb; 16(4):1562-95. PubMed ID: 18053726
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development and characterization of endocannabinoid hydrolases FAAH and MAGL inhibitors bearing a benzotriazol-1-yl carboxamide scaffold.
    Morera L; Labar G; Ortar G; Lambert DM
    Bioorg Med Chem; 2012 Nov; 20(21):6260-75. PubMed ID: 23036333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structure based design of novel irreversible FAAH inhibitors.
    Wang JL; Bowen SJ; Schweitzer BA; Madsen HM; McDonald J; Pelc MJ; Tenbrink RE; Beidler D; Thorarensen A
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5970-4. PubMed ID: 19765986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structure-activity relationship studies on 1-(2-oxopropyl)indole-5-carboxylic acids acting as inhibitors of cytosolic phospholipase A
    Arnsmann M; Hanekamp W; Elfringhoff AS; Lehr M
    Eur J Med Chem; 2017 Jan; 125():1107-1114. PubMed ID: 27810597
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors.
    Seierstad M; Breitenbucher JG
    J Med Chem; 2008 Dec; 51(23):7327-43. PubMed ID: 18983142
    [No Abstract]   [Full Text] [Related]  

  • 30. Synthesis and evaluation of benzothiazole-based analogues as novel, potent, and selective fatty acid amide hydrolase inhibitors.
    Wang X; Sarris K; Kage K; Zhang D; Brown SP; Kolasa T; Surowy C; El Kouhen OF; Muchmore SW; Brioni JD; Stewart AO
    J Med Chem; 2009 Jan; 52(1):170-80. PubMed ID: 19072118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as off-targets.
    Zhang D; Saraf A; Kolasa T; Bhatia P; Zheng GZ; Patel M; Lannoye GS; Richardson P; Stewart A; Rogers JC; Brioni JD; Surowy CS
    Neuropharmacology; 2007 Mar; 52(4):1095-105. PubMed ID: 17217969
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase.
    Gattinoni S; Simone CD; Dallavalle S; Fezza F; Nannei R; Battista N; Minetti P; Quattrociocchi G; Caprioli A; Borsini F; Cabri W; Penco S; Merlini L; Maccarrone M
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4406-11. PubMed ID: 20591666
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and biological activity of 6H-isoindolo[2,1-a]indol-6-ones, analogues of batracylin, and related compounds.
    Guillaumel J; Léonce S; Pierré A; Renard P; Pfeiffer B; Arimondo PB; Monneret C
    Eur J Med Chem; 2006 Mar; 41(3):379-86. PubMed ID: 16442188
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A MBP-FAAH fusion protein as a tool to produce human and rat fatty acid amide hydrolase: expression and pharmacological comparison.
    Labar G; Vliet FV; Wouters J; Lambert DM
    Amino Acids; 2008 Jan; 34(1):127-33. PubMed ID: 17476568
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Binding mode of new (thio)hydantoin inhibitors of fatty acid amide hydrolase: comparison with two original compounds, OL-92 and JP104.
    Michaux C; Muccioli GG; Lambert DM; Wouters J
    Bioorg Med Chem Lett; 2006 Sep; 16(18):4772-6. PubMed ID: 16844375
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and structure-activity relationships of FAAH inhibitors: cyclohexylcarbamic acid biphenyl esters with chemical modulation at the proximal phenyl ring.
    Tarzia G; Duranti A; Gatti G; Piersanti G; Tontini A; Rivara S; Lodola A; Plazzi PV; Mor M; Kathuria S; Piomelli D
    ChemMedChem; 2006 Jan; 1(1):130-9. PubMed ID: 16892344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanism of inhibition of fatty acid amide hydrolase by sulfonamide-containing benzothiazoles: long residence time derived from increased kinetic barrier and not exclusively from thermodynamic potency.
    Tian G; Paschetto KA; Gharahdaghi F; Gordon E; Wilkins DE; Luo X; Scott CW
    Biochemistry; 2011 Aug; 50(32):6867-78. PubMed ID: 21728345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 1-Heteroarylpropan-2-ones as inhibitors of fatty acid amide hydrolase: Studies on structure-activity relationships and metabolic stability.
    Zahov S; Garzinsky D; Hanekamp W; Lehr M
    Bioorg Med Chem; 2017 Feb; 25(3):825-837. PubMed ID: 27989417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 3-Heterocycle-phenyl N-alkylcarbamates as FAAH inhibitors: design, synthesis and 3D-QSAR studies.
    Käsnänen H; Myllymäki MJ; Minkkilä A; Kataja AO; Saario SM; Nevalainen T; Koskinen AM; Poso A
    ChemMedChem; 2010 Feb; 5(2):213-31. PubMed ID: 20024981
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of novel spirocyclic inhibitors of fatty acid amide hydrolase (FAAH). Part 1: identification of 7-azaspiro[3.5]nonane and 1-oxa-8-azaspiro[4.5]decane as lead scaffolds.
    Meyers MJ; Long SA; Pelc MJ; Wang JL; Bowen SJ; Walker MC; Schweitzer BA; Madsen HM; Tenbrink RE; McDonald J; Smith SE; Foltin S; Beidler D; Thorarensen A
    Bioorg Med Chem Lett; 2011 Nov; 21(21):6538-44. PubMed ID: 21924614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.